Logo Image
|Videos|June 25, 2019

Inappropriate Empiric Therapy as a Driver of Poor Outcomes

Glenn Tillotson, PhD, explains how inappropriate empiric therapy can drive poor outcomes.

Segment Description: Glenn Tillotson, PhD, consultant with GST Micro and Contagion® Editorial Advisory Board member, explains how inappropriate empiric therapy can drive poor outcomes.

Interview transcript (modified slightly for readability):

Dr. Tillotson: "Inappropriate antibiotic empiric therapy is really recognized as a driver of poor outcomes such as longer length of stay in an intensive care unit, a longer length of stay in the hospital alone, prolonged antibiotic therapy, having to swap and change, and, in some skin infections, it actually can lead to mortality. So conditions such as abscesses that are inappropriately treated those can turn into complex challenges."

Related to this article

View more
Ceftriaxone Safety: Separating Signal From Risk
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Read more
Treatment of Latent Tuberculosis in a Trice
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Read more
Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Read more